Organ Size Control Is Dominant over Rb Family Inactivation to Restrict Proliferation InVivo

Cell Reports

Volumn 8, Issue 2, 2014, Pages 371-381

  Ehmer, Ursula ^a,b   Zmoos, Anne Flore ^a   Auerbach, Raymond K ^a   Vaka, Dedeepya ^a   Butte, Atul J ^a   Kay, Mark A ^a   Sage, Julien ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR YAP; UNCLASSIFIED DRUG; TRANSCRIPTION FACTOR E2F; ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR; CYCLIN DEPENDENT KINASE INHIBITOR 1A; PHOSPHOPROTEIN; PROTEIN P107; PROTEIN P130; RBL1 PROTEIN, MOUSE; RBL2 PROTEIN, MOUSE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; YAP PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARF GENE; ARTICLE; CELL CYCLE ARREST; CELL CYCLE CHECKPOINT; CELL CYCLE REGULATION; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE; GENE DELETION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE INACTIVATION; GENE INTERACTION; GENE LOSS; GENETIC CORRELATION; GROWTH REGULATION; IN VIVO STUDY; LIVER CELL; LIVER SIZE; MOUSE; NONHUMAN; ORGAN GROWTH; ORGAN SIZE; P21 GENE; P53 GENE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RB GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; YAP GENE; ADULT; GENE EXPRESSION; ANIMAL; CYTOLOGY; GENETICS; GROWTH, DEVELOPMENT AND AGING; LIVER; METABOLISM; PHYSIOLOGY;

MAMMALIA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADP-RIBOSYLATION FACTORS; ANIMALS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENES, CDC; HEPATOCYTES; LIVER; MICE; ORGAN SIZE; PHOSPHOPROTEINS; RETINOBLASTOMA-LIKE PROTEIN P107; RETINOBLASTOMA-LIKE PROTEIN P130; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84904814939     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.06.025     Document Type: Article

References (42)

1. Ajioka I., Martins R.A., Bayazitov I.T., Donovan S., Johnson D.A., Frase S., Cicero S.A., Boyd K., Zakharenko S.S., Dyer M.A. Differentiated horizontal interneurons clonally expand to form metastatic retinoblastoma in mice. Cell 2007, 131:378-390.
2. Aksoy O., Chicas A., Zeng T., Zhao Z., McCurrach M., Wang X., Lowe S.W. The atypical E2F family member E2F7 couples the p53 and RB pathways during cellular senescence. Genes Dev. 2012, 26:1546-1557.
3. Auerbach R.K., Chen B., Butte A.J. Relating genes to function: identifying enriched transcription factors using the ENCODE ChIP-Seq significance tool. Bioinformatics 2013, 29:1922-1924.
4. Avruch J., Zhou D., Fitamant J., Bardeesy N. Mst1/2 signalling to Yap: gatekeeper for liver size and tumour development. Br. J. Cancer 2011, 104:24-32.
5. Cheng L., Zhou Z., Flesken-Nikitin A., Toshkov I.A., Wang W., Camps J., Ried T., Nikitin A.Y. Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency. Oncogene 2010, 29:5700-5711.
6. Dannenberg J.H., van Rossum A., Schuijff L., te Riele H. Ablation of the retinoblastoma gene family deregulates G(1) control causing immortalization and increased cell turnover under growth-restricting conditions. Genes Dev. 2000, 14:3051-3064.
7. Dannenberg J.H., Schuijff L., Dekker M., van der Valk M., te Riele H. Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107 and p130. Genes Dev. 2004, 18:2952-2962.
8. Dick F.A., Rubin S.M. Molecular mechanisms underlying RB protein function. Nat. Rev. Mol. Cell Biol. 2013, 14:297-306.
9. Dong J., Feldmann G., Huang J., Wu S., Zhang N., Comerford S.A., Gayyed M.F., Anders R.A., Maitra A., Pan D. Elucidation of auniversal size-control mechanism in Drosophila and mammals. Cell 2007, 130:1120-1133.
10. Duncan A.W. Aneuploidy, polyploidy and ploidy reversal in the liver. Semin. Cell Dev. Biol. 2013, 24:347-356.
11. Duncan A.W., Dorrell C., Grompe M. Stem cells and liver regeneration. Gastroenterology 2009, 137:466-481.
12. Garfin P.M., Min D., Bryson J.L., Serwold T., Edris B., Blackburn C.C., Richie E.R., Weinberg K.I., Manley N.R., Sage J., Viatour P. Inactivation of the RB family prevents thymus involution and promotes thymic function by direct control of Foxn1 expression. J.Exp. Med. 2013, 210:1087-1097.
13. Hiyama H., Iavarone A., Reeves S.A. Regulation of the cdk inhibitor p21 gene during cell cycle progression is under the control of the transcription factor E2F. Oncogene 1998, 16:1513-1523.
14. Jiang Z., Deng T., Jones R., Li H., Herschkowitz J.I., Liu J.C., Weigman V.J., Tsao M.S., Lane T.F., Perou C.M., Zacksenhaus E. Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J.Clin. Invest. 2010, 120:3296-3309.
15. Kapoor A., Yao W., Ying H., Hua S., Liewen A., Wang Q., Zhong Y., Wu C.J., Sadanandam A., Hu B., et al. Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer. Cell 2014, 158:185-197.
16. Lu L., Li Y., Kim S.M., Bossuyt W., Liu P., Qiu Q., Wang Y., Halder G., Finegold M.J., Lee J.S., Johnson R.L. Hippo signaling is a potent invivo growth and tumor suppressor pathway in the mammalian liver. Proc. Natl. Acad. Sci. USA 2010, 107:1437-1442.
17. Manning A.L., Dyson N.J. RB: mitotic implications of a tumour suppressor. Nat. Rev. Cancer 2012, 12:220-226.
18. Mayhew C.N., Bosco E.E., Fox S.R., Okaya T., Tarapore P., Schwemberger S.J., Babcock G.F., Lentsch A.B., Fukasawa K., Knudsen E.S. Liver-specific pRB loss results in ectopic cell cycle entry and aberrant ploidy. Cancer Res. 2005, 65:4568-4577.
19. McClendon A.K., Dean J.L., Ertel A., Fu Z., Rivadeneira D.B., Reed C.A., Bourgo R.J., Witkiewicz A., Addya S., Mayhew C.N., et al. RB and p53 cooperate to prevent liver tumorigenesis in response to tissue damage. Gastroenterology 2011, 141:1439-1450.
20. McEvoy J., Flores-Otero J., Zhang J., Nemeth K., Brennan R., Bradley C., Krafcik F., Rodriguez-Galindo C., Wilson M., Xiong S., et al. Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. Cancer Cell 2011, 20:260-275.
21. Nicolay B.N., Dyson N.J. The multiple connections between pRB and cell metabolism. Curr. Opin. Cell Biol. 2013, 25:735-740.
22. Nicolay B.N., Bayarmagnai B., Moon N.S., Benevolenskaya E.V., Frolov M.V. Combined inactivation of pRB and hippo pathways induces dedifferentiation in the Drosophila retina. PLoS Genet. 2010, 6:e1000918.
23. Nicolay B.N., Bayarmagnai B., Islam A.B., Lopez-Bigas N., Frolov M.V. Cooperation between dE2F1 and Yki/Sd defines a distinct transcriptional program necessary to bypass cell cycle exit. Genes Dev. 2011, 25:323-335.
24. O'Geen H., Nicolet C.M., Blahnik K., Green R., Farnham P.J. Comparison of sample preparation methods for ChIP-chip assays. Biotechniques 2006, 41:577-580.
25. Oh H., Slattery M., Ma L., Crofts A., White K.P., Mann R.S., Irvine K.D. Genome-wide association of Yorkie with chromatin and chromatin-remodeling complexes. Cell Reports 2013, 3:309-318.
26. Robanus-Maandag E., Dekker M., van der Valk M., Carrozza M.L., Jeanny J.C., Dannenberg J.H., Berns A., te Riele H. p107 is a suppressor of retinoblastoma development in pRb-deficient mice. Genes Dev. 1998, 12:1599-1609.
27. Rosenbluh J., Nijhawan D., Cox A.G., Li X., Neal J.T., Schafer E.J., Zack T.I., Wang X., Tsherniak A., Schinzel A.C., et al. β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 2012, 151:1457-1473.
28. Sage J., Mulligan G.J., Attardi L.D., Miller A., Chen S., Williams B., Theodorou E., Jacks T. Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. Genes Dev. 2000, 14:3037-3050.
29. Sage J., Miller A.L., Pérez-Mancera P.A., Wysocki J.M., Jacks T. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 2003, 424:223-228.
30. Schuler M., Dierich A., Chambon P., Metzger D. Efficient temporally controlled targeted somatic mutagenesis in hepatocytes of the mouse. Genesis 2004, 39:167-172.
31. Shao D.D., Xue W., Krall E.B., Bhutkar A., Piccioni F., Wang X., Schinzel A.C., Sood S., Rosenbluh J., Kim J.W., et al. KRAS and YAP1 Converge to Regulate EMT and Tumor Survival. Cell 2014, 158:171-184.
32. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102:15545-15550.
33. Symonds H., Krall L., Remington L., Saenz-Robles M., Lowe S., Jacks T., Van Dyke T. p53-dependent apoptosis suppresses tumor growth and progression invivo. Cell 1994, 78:703-711.
34. Tschöp K., Conery A.R., Litovchick L., Decaprio J.A., Settleman J., Harlow E., Dyson N. A kinase shRNA screen links LATS2 and the pRB tumor suppressor. Genes Dev. 2011, 25:814-830.
35. Viatour P., Somervaille T.C., Venkatasubrahmanyam S., Kogan S., McLaughlin M.E., Weissman I.L., Butte A.J., Passegué E., Sage J. Hematopoietic stem cell quiescence is maintained by compound contributions of the retinoblastoma gene family. Cell Stem Cell 2008, 3:416-428.
36. Viatour P., Ehmer U., Saddic L.A., Dorrell C., Andersen J.B., Lin C., Zmoos A.F., Mazur P.K., Schaffer B.E., Ostermeier A., et al. Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J.Exp. Med. 2011, 208:1963-1976.
37. Xu X., Bieda M., Jin V.X., Rabinovich A., Oberley M.J., Green R., Farnham P.J. A comprehensive ChIP-chip analysis of E2F1, E2F4, and E2F6 in normal and tumor cells reveals interchangeable roles of E2F family members. Genome Res. 2007, 17:1550-1561.
38. Yant S.R., Meuse L., Chiu W., Ivics Z., Izsvak Z., Kay M.A. Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat. Genet. 2000, 25:35-41.
39. Zender L., Xue W., Cordón-Cardo C., Hannon G.J., Lucito R., Powers S., Flemming P., Spector M.S., Lowe S.W. Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors. Cold Spring Harb. Symp. Quant. Biol. 2005, 70:251-261.
40. Zhang B., Kirov S., Snoddy J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res. 2005, 33. W741-8.
41. Zhao B., Wei X., Li W., Udan R.S., Yang Q., Kim J., Xie J., Ikenoue T., Yu J., Li L., et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007, 21:2747-2761.
42. Zhou D., Conrad C., Xia F., Park J.S., Payer B., Yin Y., Lauwers G.Y., Thasler W., Lee J.T., Avruch J., Bardeesy N. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 2009, 16:425-438.